Maralixibat chloride, sold under the brand name Livmarli, is a medication used to treat cholestatic pruritus in people with Alagille syndrome. Maralixibat chloride is an ileal bile acid transporter (IBAT) inhibitor.
The most common side effects include diarrhea and abdominal pain (belly ache).
Maralixibat chloride was approved for medical use in the United States in September 2021, and in the European Union in December 2022.
Medical uses Maralixibat chloride is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome.
History The U.S. Food and Drug Administration (FDA) granted the application for maralixibat chloride orphan drug designations in 2013, and in 2020.
Society and culture Legal status In October 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Livmarli, intended for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). The applicant for this medicinal product is Mirum Pharmaceuticals International B.V. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. Maralixibat chloride was approved for medical use in the European Union in December 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Names Maralixibat chloride is the international nonproprietary name (INN).
References
External links